Literature DB >> 24048634

Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses.

Mariasanta Napolitano1, Alberto Dolce, Giuseppe Celenza, Elvira Grandone, Maria Grazia Perilli, Sergio Siragusa, Gaspare Carta, Assunta Orecchioni, Guglielmo Mariani.   

Abstract

In women of fertile age, iron loss consequent to excessive menstrual discharge is by far the most frequent cause of iron-deficient anemia. However, the relationship between menstrual discharge and iron loss is poorly understood. In this prospective study, total menstrual and iron losses were assayed in a large cohort of non-anemic women and women with excessive menstrual blood losses (menorrhagia) in order to provide data useful for intervention. One hundred and five Caucasian women aged 20-45 years were recruited. Blood cell count and serum ferritin (SF) levels were determined in each case before menses. Menstrual fluid losses (MFL) were determined using a standardized pads' weight method. Hematin concentration was assayed by a variant of the Alkaline Hematin Method from which iron concentration was calculated. Mean SF levels were 36.2 (range 8.6-100) ng/ml in healthy women and 6.4 (range 5-14) ng/ml in patients with menorrhagia. Median values of iron lost/cycle were 0.87 mg in healthy women and 5.2 mg in patients with menorrhagia (ranges 0.102-2.569 and 1.634-8.665 mg, respectively, p < 0.001). In women with menorrhagia, iron lost/cycle strongly correlated (0.789, p < 0.001) with MFL. In conclusion, healthy women with normal menses lose, on average, 1 mg iron/cycle. Average iron losses in patients with menorrhagia are, at least in our cohort, on average, five-to-six times higher than normal. Most women with menorrhagia had totally depleted iron stores. Indirect, quantitative evaluation of iron lost with menses may be useful to assess the risk of developing iron-deficient anemia in individual patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24048634     DOI: 10.1007/s00277-013-1901-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  14 in total

1.  Case-based discussion on the implications of exogenous estrogens in hemostasis and thrombosis: the hematologist's view.

Authors:  Margaret V Ragni
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 2.  [Diagnostic approach to iron deficiency anemia].

Authors:  Kristine Jimenez; Michaela Lang
Journal:  Wien Med Wochenschr       Date:  2016-08-26

Review 3.  Iron overload in the HCT patient: a review.

Authors:  Pavan Tenneti; Aleksander Chojecki; Mary Ann Knovich
Journal:  Bone Marrow Transplant       Date:  2021-03-29       Impact factor: 5.174

Review 4.  Factor VII Deficiency: Clinical Phenotype, Genotype and Therapy.

Authors:  Mariasanta Napolitano; Sergio Siragusa; Guglielmo Mariani
Journal:  J Clin Med       Date:  2017-03-28       Impact factor: 4.241

5.  A systematic review of methods to measure menstrual blood loss.

Authors:  Julia L Magnay; Shaughn O'Brien; Christoph Gerlinger; Christian Seitz
Journal:  BMC Womens Health       Date:  2018-08-22       Impact factor: 2.809

Review 6.  Iron Deficiency and Iron Deficiency Anemia: Implications and Impact in Pregnancy, Fetal Development, and Early Childhood Parameters.

Authors:  Robert T Means
Journal:  Nutrients       Date:  2020-02-11       Impact factor: 5.717

7.  Association between Anemia and Stroke in Females: A Nationwide, Population-Based Cohort Study in Taiwan.

Authors:  Yuan Sui; Chien-Tai Hong; Li-Nien Chien; Hung-Yi Liu; Hung-Yi Chiou; Yi-Chen Hsieh
Journal:  Int J Environ Res Public Health       Date:  2020-10-13       Impact factor: 3.390

8.  Do pregnancies reduce iron overload in HFE hemochromatosis women? results from an observational prospective study.

Authors:  Virginie Scotet; Philippe Saliou; Marianne Uguen; Carine L'Hostis; Marie-Christine Merour; Céline Triponey; Brigitte Chanu; Jean-Baptiste Nousbaum; Gerald Le Gac; Claude Ferec
Journal:  BMC Pregnancy Childbirth       Date:  2018-02-17       Impact factor: 3.007

9.  [Congenital factor Ⅶ deficiency: a retrospective analysis of 43 cases].

Authors:  C Y Qu; D L Zhang; X F Liu; F Xue; W Liu; Y F Chen; R F Fu; L Zhang; R C Yang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14

10.  Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.

Authors:  James A Simon; Ayman Al-Hendy; David F Archer; Kurt T Barnhart; Linda D Bradley; Bruce R Carr; Thomas Dayspring; Eve C Feinberg; Veronica Gillispie; Sandra Hurtado; JinHee Kim; Ran Liu; Charlotte D Owens; Ozgul Muneyyirci-Delale; Alice Wang; Nelson B Watts; William D Schlaff
Journal:  Obstet Gynecol       Date:  2020-06       Impact factor: 7.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.